Cardiac side effects of trastuzumab: Lessons learned from targeting cancer pathways: Commentary

Nature Clinical Practice Oncology

Volumn 4, Issue 4, 2007, Pages 220-221

  Tripathy, Debu ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FOLLOW UP; GENE OVEREXPRESSION; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY; SIDE EFFECT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 34047120770     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0768     Document Type: Short Survey

References (4)

1. Seidman A et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221
2. Lee KF et al. (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378: 394-398
3. Crone SA et al. (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459-465
4. Tripathy D et al. (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 15: 1063-1070